Clinical Trial Update: A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial updating enzyme replacement therapy VPRIV in people with Gaucher disease previously treated with substrate reduction therapy; results posted after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• VPRIV (VELAGLUCERASE ALFA)

Snippet

Sponsor: Takeda | Conditions: Gaucher Disease | Phase 4 | Status: COMPLETED | Results posted: 2023-12-21